PDUFA dates November 2023: FDA calendar and catalysts.
2 PDUFA dates fell in November 2023: ABEO (Nov 2023), reproxalap (November 23). The FDA calendar also recorded 30 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in November 2023
| PDUFA date | Company | Ticker | Drug | Indication | Source |
|---|---|---|---|---|---|
| Nov 2023 | ABEONA THERAPEUTICS INC. | ABEO | Not named | SEC Form 10-K, filed 2025-03-20 | |
| November 23, 2023 | Aldeyra Therapeutics, Inc. | ALDX | reproxalap | SEC Form 10-Q, filed 2025-05-14 |
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
November 2023: other FDA decisions and filings
November 2023: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Nov 2023Month disclosed | Simponi® | ALVO | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Nov 2023Month disclosed | fluoroquinolone | INVA | Topline readout | — | Positive | SEC Form 10-K |
| Nov 2023Month disclosed | PSA-201 | MLTX | Topline readout | active PsA | Met primary endpoint | SEC Form 10-Q |
| November 30, 2023 | HLP003 | HELP | Topline readout | — | Met primary endpoint | SEC 8-K Exhibit 99.1 |
| November 30, 2023 | CYB003 | HELP | Topline readout | — | Met primary endpoint | SEC 8-K Exhibit 99.1 |
November 2023: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Nov 2023Month disclosed | GOHIBIC (vilobelimab) | IFRX | Trial start | — | Completed | SEC Form 10-K |
| Nov 2023Month disclosed | remlifanserin (ACP-204) | ACAD | Trial start | hallucinations and delusions associated with ADP | Completed | SEC Form 10-Q |
| Nov 2023Month disclosed | pipe-307 dose a (PIPE-307) | CTNM | Trial start | RRMS, referred to | Completed | SEC Form 10-K |
| Nov 2023Month disclosed | PSA-201 | MLTX | Trial start | active PsA | Completed | SEC Form 10-Q |
| November 6, 2023 | lanifibranor (IVA337) | IVA | Trial start | T2D and NAFLD sponsored | Completed | SEC Form 10-K |
| Nov 2023Month disclosed | AMT-19 | QURE | Trial start | — | Completed | SEC Form 10-Q |
| Nov 2023Month disclosed | AMT-191 | QURE | Trial start | — | Completed | SEC Form 10-K |
| Nov 2023Month disclosed | APHEXDA® (motixafortide) | BLRX | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
Questions
What PDUFA dates are in November 2023?
2 PDUFA dates fell in November 2023: ABEO (Nov 2023), reproxalap (November 23). The FDA calendar also recorded 30 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.